Bli medlem
Bli medlem

Du är här

2016-11-16

Nordic Nanovector: Nordic Nanovector ASA: Third Quarter 2016 Results Presentation and Webcast

Date: 16.11.2016        Press Release no: 58/2016

Oslo, Norway, 16 November 2016

Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on
the development and commercialisation of novel targeted therapeutics
in haematology and oncology, will announce its third quarter 2016
results on Wednesday, 23 November 2016.

A presentation by Nordic Nanovector's senior management team will take
place at 8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: BJØRVIKA

The presentation will be recorded as a webcast and will be available
at www.nordicnanovector.com in the section: Investor
Relations/Webcast.

The results report and the presentation will be available at
www.nordicnanovector.com in the section: Investor Relations/Reports
and Presentation/Quarterly Reports/2016 from 7:00 am CET the same
day.

###

For further information, please contact:

IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: mark.swallow@citigatedr.co.uk / david.dible@citigatedr.co.uk

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity
radionuclide (lutetium-177). The preliminary data has shown promising
efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with
first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline
to treat multiple selected cancer indications.

Further information about the Company can be found at
www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

-----------------------------------------------------------
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--third-...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.